Eli Lilly is betting up to $630 million on an experimental MASH treatment from a South Korean biotech. The pharma giant announced a deal on Monday to license a Phase 1 candidate called OLX75016 from ...
Twenty-two state attorneys general sued the Trump administration on Monday in a bid to halt a new cap on indirect costs for ...
Several brand-name drugmakers believe they will withstand any drug pricing impacts from President Donald Trump’s tariffs — ...
Novo Nordisk hit back at telehealth company Hims’ controversial Super Bowl commercial touting cheaper versions of brand-name ...
Boehringer Ingelheim said its experimental treatment for a chronic lung disease succeeded in a pivotal study, and it's taking ...
Roche's $8 billion InterMune acquisition, disclosed a decade ago, is now being handed to a specialty pharmaceutical company.
Pliant Therapeutics has slammed the brakes on enrollment and dosing in a mid-stage study of its lung disease ...
Roivant ends namilumab program, Bio-Thera partners on golimumab biosimilar, Caliway advances fat treatment, Orca Bio's T cell success, funding for Alterity & Ascentage ...
Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...
Sens. Dick Durbin (D-IL) and Roger Marshall (R-KS) are calling on the FDA to take action against a Super Bowl ad coming on ...
It took one month for Johnson & Johnson to secure its $14 billion acquisition of Intra-Cellular Therapies, according to new ...
Indian drugmaker Maithili Life Sciences has received a non-compliant report from the Brussels-based Federal Agency for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback